← Human Trials & Peer-Reviewed Studies
Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight
Plain-language guide to PMID 41135142 (2025): double-blind randomized controlled trial study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 41135142
- Journal
- Sleep medicine
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Malhotra A et al. (9 authors)
- DOI
- 10.1016/j.sleep.2025.106853
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
The researchers also aimed to investigate weight-dependent and weight-independent effects of tirzepatide treatment for OSA using linear regression analysis.
Why It Was Studied
Obstructive sleep apnea (OSA) is a common disorder with major cardiometabolic and neurocognitive sequelae.
It affects up to 1 billion people globally and is frequently attributable to excess weight [1].
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
Because people in this Tirzepatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.
The comparison arm used a placebo, so changes seen with Tirzepatide could be set against what happens without it.
The SURMOUNT-OSA program included two 52-week, randomized, double-blind, placebo-controlled, Phase 3 studies (Study 1 and Study 2).
What Was Measured
The subject headings attached to it are Sleep Apnea, Obstructive, Obesity, Gastric Inhibitory Polypeptide, Polysomnography, Sleep Apnea Syndromes and Tirzepatide.
Author keywords: Apnea-hypopnea index, Obstructive sleep apnea, SURMOUNT-OSA and Sleep apnea-specific hypoxic burden.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide).
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2025 (Sleep medicine), a journal based in Netherlands.
More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compounds
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.